Ex­pert pan­el re­view on Alzheimer’s drug ad­u­canum­ab be­comes a one-day tri­al by fire as crit­ics turn their guns on ...

5 years ago
FDA+

As­traZeneca gets a much-need­ed boost for blood thin­ner Bril­in­ta with an OK on stroke

5 years ago
FDA+

Karin Rosén moves on from GSK, now play­ing dual roles at Hori­zon; Gilead looks to Jared Baeten to take com­mand of ...

5 years ago
Peer Review

News brief­ing: Chi­nese can­cer play­er gets $124M+ Se­ries C; IN8bio sets terms for $86M IPO

5 years ago
News Briefing

Sanofi hits the brakes on a top piv­otal pro­gram fol­low­ing 'new ad­verse events'

5 years ago
R&D

Covid-19 roundup: No­var­tis treat­ment comes up short in PhI­II; Hu­mani­gen ex­pands tri­al, but draws crit­i­cism

5 years ago
Coronavirus

The FDA's in­sid­er re­view on ad­u­canum­ab was all about pol­i­tics, not sci­ence, and it threat­ens pa­tients and the ...

5 years ago
Bioregnum
FDA+

Two years af­ter a re­buffed ac­tivist at­tack, Alex Den­ner fi­nal­ly gets his seat on Iron­wood's board

5 years ago
People

En­do Phar­ma­ceu­ti­cals chops 560 jobs to re­fo­cus on cel­lulite drug launch

5 years ago
Outsourcing
Pharma

Cit­ing pan­dem­ic, Sarep­ta de­fers much-an­tic­i­pat­ed DMD gene ther­a­py PhI­II, will head to reg­u­la­tors af­ter 10-per­son ...

5 years ago
Cell/Gene Tx
FDA+

No­vo Nordisk bolts on a ‘holy grail’ oral de­liv­ery plat­form in $1.8B buy­out

5 years ago
Deals

As­sem­bly Bio's he­pati­tis B pro­gram flops as a po­ten­tial cure in PhII, send­ing shares spi­ral­ing

5 years ago
R&D

News brief­ing: Cosen­tyx shows ear­ly pos­i­tive signs in pso­ri­at­ic arthri­tis; Pfiz­er's PhI­Ib for car­dio drug trig­gers ...

5 years ago
News Briefing

Lat­est J&J-part­nered Leg­end Biotech da­ta spot­light con­tin­ued high re­sponse rate but 10 pa­tient deaths

5 years ago
R&D

Bris­tol My­ers hints at some prob­lems with an FDA in­spec­tion need­ed for the liso-cel OK, and the Cel­gene CVR in­vestors ...

5 years ago
R&D
FDA+

Bio­Marin gets its dwarfism drug in the FDA's door — but can they change reg­u­la­tors’ minds about a longer fol­low ...

5 years ago
FDA+

What do the top 10 biotech M&A deals of 2020 tell us? Pre­mi­ums are in, bolt-ons rule and the ADC come­back is on

5 years ago
Startups
Deals

FDA scut­tles blue­bird's ac­cel­er­at­ed plans for sick­le cell gene ther­a­py, as high­er CMC bar forces 1-year de­lay

5 years ago
Outsourcing
Cell/Gene Tx

Covid-19 roundup: So­ri­ot — vac­cine could be ready by year's end; WHO omits remde­sivir from de­vel­op­ing coun­tries ...

5 years ago
Coronavirus

Pa­tient death mars lat­est cut of da­ta from Al­lo­gene's off-the-shelf CAR-T

5 years ago
R&D
Cell/Gene Tx

In­spired by ASH da­ta, Mer­ck­'s Roger Perl­mut­ter swoops in with a $2.75B ROR1 buy­out aimed at beef­ing up the can­cer ...

5 years ago
Deals

Am­gen and No­var­tis back Aimovig with new da­ta as mi­graine com­pe­ti­tion heats up

5 years ago
R&D

A year af­ter stun­ning Chi­na OK, Shang­hai Alzheimer's drug­mak­er set to en­roll first US pa­tient — and the stakes are ...

5 years ago
R&D
China

Ver­tex, fresh off an R&D miss, flash­es da­ta sug­gest­ing their sick­le cell CRISPR ther­a­py is work­ing

5 years ago
R&D
Cell/Gene Tx
First page Previous page 780781782783784785786 Next page Last page
A service from the Financial Times